Dealmaker Breaks Down The Daiichi Sankyo-Ranbaxy Deal: PharmAsia News Spotlight
This article was originally published in PharmAsia News
Executive Summary
Japan health care reforms enacted in April aimed at increasing the use of generics helped set the stage for the watershed deal between Daiichi Sankyo and Ranbaxy, and will have major implications for Indian generics companies, according to Mehta Partners, the Indian firm that brokered the deal on behalf of Daiichi
You may also be interested in...
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings
As Big Pharma Eye Big Buyouts In India, Merck KGaA Goes With Bangalore Genei To Sharpen Edge In Biologicals
MUMBAI - Away from the high decibel market speculation about moves made by Big Pharma to acquire large-sized companies in India, Darmstadt, Germany-headquartered Merck KGaA quietly picked up a little known molecular biology company called Bangalore Genei, which it claimed will help it "become one of the leading bioscience companies in India.